Tag: M.W:100-200

1837-55-4, Chemistry, like all the natural sciences, begins with the direct observation of nature¡ª in this case, of matter. In a patent£¬patent Assignee is CANDITO, David Annunziato, Which mentioned a new discovery about 1837-55-4, molecular formula is C4H2Cl2N2.

INDAZOLYL-SPIRO[2.2]PENTANE-CARBONITRILE DERIVATIVES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF

The present invention is directed to substituted certain reversed indazolyl-spiro[2.2]pentane-carbonitrile derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, X, Y, and Z are as defined herein, which are potent inhibitors of LRRK2 kinase and may be useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson’s Disease and other diseases and disorders described herein. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which LRRK-2 kinase is involved.

Enzymes are biological catalysts that produce large increases in reaction rates and tend to be specific for certain reactants and products. I hope my blog about is helpful to your research. 1837-55-4

Reference£º
Pyridazine – Wikipedia,
Pyridazine | C4H4N1153 – PubChem

 

Catalysts function by providing an alternate reaction mechanism that has a lower activation energy than would be found in the absence of the catalyst. In a patent, 19064-67-6, molecular formula is C4H3ClN2O, introducing its new discovery. 19064-67-6

NEW DERIVATIVES OF 6-4{4-[1H-INDOLE-2-SULPHONYL)-PIPERAZIN-1-CARBONYL-PHENYL]}PYRADIZIN-3-ONE

The invention relates to heterocyclic derivatives of formula (I), wherein R2 is amino, a group OR4 or a group-Y-R5 where R4 is hydrogen or C1-4alkyl, Y is C1-4alkylene, R 5 is hydrogen, halo, hydroxy, C1-2alkoxy, C1-2alkoxyC 1-2alkoxyC1-4, or a group NR7R8 where R7 and R8 are independently selected from hydrogen, C1-2alkyl, hydroxyC1-2alkyl or alkoxyC1-2alkyl, or R7 and R8 together with the nitrogen atom to which they are attached form a saturated 5-6-membered heterocyclic ring which optionally contains an additional heteroatom; n is one or two and each R1 is independently selected from halo, haloC1-2alkyl, hydroxy, oxo, amino, C1-2alkylamino or di-C1-2 dialkylamino; or a pharmaceutically acceptable salt thereof. These compounds possess antithrombotic and anticoagulant properties and are accordingly useful in methods of treatment of humans or animals. The invention also relates to processes for the preparation of the heterocyclic derivatives, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments for use in the production of an antithrombotic or anticoagulant effect.

19064-67-6, Interested yet? Read on for other articles about 19064-67-6!

Reference£º
Pyridazine – Wikipedia,
Pyridazine | C4H4N720 – PubChem

 

64068-00-4, Catalysts function by providing an alternate reaction mechanism that has a lower activation energy than would be found in the absence of the catalyst. In some cases, the catalyzed mechanism may include additional steps.In a article, 64068-00-4, molcular formula is C5H6ClN3, introducing its new discovery.

Cyclic alkylidenyl N-[6-(amino)-3-pyridazinyl]aminomethylenemalonates

Compounds useful as schistosomicidal agents are cyclic alkylidenyl N-[6-(R3 R4 N)-4(or 5)-R5 -3-pyridazinyl]aminomethylenemalonates (I), where R3 R4 N is lower-tertiary-amino and R5 is hydrogen or lower-alkyl, are prepared by reacting 3-amino-6-(R3 R4 N)-4(or 5)-R5 -pyridazine (III) with cyclic alkylidenyl alpha-(lower-alkoxymethylene)malonate (IV) or by heating equimolar quantities of III, tri-(lower-alkyl) orthoformate and cyclic alkylidenyl malonate (V). Also shown is cyclic isopropylidenyl N-(6-methylamino-3-pyridazinyl)aminomethylenemalonate, a schistosomicidal agent, and its preparation. Also shown are schistosomicidal compositions comprising as active component a schistosomicidally effective cyclic alkylidenyl N-[6-(R3 R4 N)-4(or 5)-R5 -3-pyridazinyl]aminomethylenemalonate (I) or cyclic isopropylidenyl N-(6-methylamino-3-pyridazinyl)aminomethylenemalonate (II) or salt thereof and a method for the treatment of schistosomiasis which comprises administering to a host infected with schistosomes a schistosomicidally effective amount of said active component.

Because enzymes can increase reaction rates by enormous factors and tend to be very specific, 64068-00-4, typically producing only a single product in quantitative yield, they are the focus of active research.you can also check out more blogs about 64068-00-4

Reference£º
Pyridazine – Wikipedia,
Pyridazine | C4H4N1046 – PubChem

 

An article , which mentions 53896-49-4, molecular formula is C5H3N3. The compound – Pyridazine-3-carbonitrile played an important role in people’s production and life., 53896-49-4

Novel thiosemicarbazones derived from formyl- and acyldiazines: Synthesis, effects on cell proliferation, and synergism with antiviral agents

The synthesis of a series of novel thiosemicarbazones (TSC’s) derived from various alkyl diazinyl (3-pyridazinyl, 4-pyrimidinyl, 2-pyrazinyl) ketones and 3-pyridazinecarbaldehyde and their evaluation against herpes simplex virus (HSV) and human immunodeficiency virus (HIV) as well as the determination of their cytotoxicity are described. In addition, the effects of combination of such TSC’s with the well-known antiviral drugs acyclovir (ACV) and 3′-azido-3′-deoxythymidine (AZT) were studied. Under our experimental conditions, i.e. determination of virus-induced cytopathic effect upon infection of HUT78 cells with HSV-1 and upon infection of MT4 cells with HIV-1, no antiviral activity could be detected with any of the TSC’s. However, pronounced effects on proliferation of these rapidly growing T4 lymphocyte cell lines were observed. Clear structure-activity relationships with regard to these cytotoxic effects could be established: compared to pyridine, pyrazine, or pyrimidine-derived TSC’s most of the 3- pyridazinyl congeners investigated are less cytotoxic: introduction of a methyl group into C-6 of the pyridazine system or prolongation of the acyl moiety in these compounds has essentially no influence; all compounds bearing an N,N-dimethylamino or a cycloamino substituent are much more toxic than those with an NH2 or NHR substituent; the nature of R in the latter type of compounds has only moderate influence. It has been reported that combination of TSC’s with the antiviral agent acyclovir (ACV) results in potentiation of this well-known drug. We evaluated the potential of our series of novel TSC’s in combination with ACV for inhibition of HSV-1-induced cytopathic effect in HUT78 cells and in combination with 3′-azido-3′-deoxythymidine (AZT) for inhibition of HIV-1-induced cytopathic effect in MT4 cells. Only four compounds out of this series, all characterized by an unsubstituted NH2 group, exhibited moderate synergism with the above mentioned antiviral drugs. Our results do not support the previously expressed opinion that TSC’s are selective antiviral agents. In our test systems no evidence for inhibition of virus-induced cytopathic effect was obtained. The TSC derivatives exhibited a broad range of cytotoxic effects, some at concentrations considerably below those reported to have antiviral efficacy. Several of our novel diazine- derived compounds proved advantageous over the previously described pyridine analogues with regard to cytotoxicity. Moderate synergism could be detected for relatively noncytotoxic TSC’s with the antiviral drugs ACV (antiherpes) and AZT (anti-HIV).

But sometimes, even after several years of basic chemistry education, it is not easy to form a clear picture on how they govern reactivity! Read on for other articles about 19493-44-8!, 53896-49-4

Reference£º
Pyridazine – Wikipedia,
Pyridazine | C4H4N190 – PubChem

 

Chemistry is traditionally divided into organic and inorganic chemistry. 932-22-9, The former is the study of compounds containing at least one carbon-hydrogen bonds.In a patent£¬Which mentioned a new discovery about 932-22-9

PYRIDAZINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER

The invention relates to compounds of formula (I) and salts thereof: wherein R1-R3 have any of the values defined in the specification. The compounds and salts are useful for treating PCAF mediated disorders and/or GCN5 mediated disorders. The invention also provides pharmaceutical compositions comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, as well as and methods of using said compounds, salts, or compositions in the treatment of various disorders.

One of the oldest and most widely used commercial enzyme inhibitors is aspirin, 932-22-9, which selectively inhibits one of the enzymes involved in the synthesis of molecules that trigger inflammation. you can also check out more blogs about 932-22-9

Reference£º
Pyridazine – Wikipedia,
Pyridazine | C4H4N2225 – PubChem

 

Catalysts function by providing an alternate reaction mechanism that has a lower activation energy than would be found in the absence of the catalyst. In some cases, the catalyzed mechanism may include additional steps.In a article, 38732-07-9, molcular formula is C5H6N2O2, introducing its new discovery. 38732-07-9

DERIVATIVES OF 2H PYRIDAZIN-3-ONES, THEIR PREPARATION AND THEIR USE AS SCD-1 INHIBITORS

The present invention concerns compounds of general formula (I) characterized in that (formula 1) wherein, in particular: -R1 represents one or more groups such as: trifluoromethyl, halogen such as F, Cl, -when n=m=1, W represents CH then Y represents oxygen, -U represents: either – (C=O) CH2NH- and is branched at position 4 of pyridazinone, then R2 represents H, or -(C=O) NH- and U is branched at positions (4), (5) or (6) of pyridazinone, then R2 represents H, – R3 represents a hydrogen or methyl and the addition salts with pharmaceutically acceptable bases and acids and the different isomers, and their mixtures in any proportion for use as SCD-1 enzyme inhibitors for the treatment of obesity, type-2 diabetes and lipid disorders

Because enzymes can increase reaction rates by enormous factors and tend to be very specific, 38732-07-9, typically producing only a single product in quantitative yield, they are the focus of active research.you can also check out more blogs about 38732-07-9

Reference£º
Pyridazine – Wikipedia,
Pyridazine | C4H4N518 – PubChem

 

1837-55-4, Catalysts function by providing an alternate reaction mechanism that has a lower activation energy than would be found in the absence of the catalyst. In a patent, 1837-55-4, molecular formula is C4H2Cl2N2, introducing its new discovery.

TRIAZOLYL PDE10 INHIBITORS

The present invention is directed to substituted triazolyl compounds which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington’s disease, and those associated with striatal hypofunction or basal ganglia dysfunction

Note that a catalyst decreases the activation energy for both the forward and the reverse reactions and hence accelerates both the forward and the reverse reactions.1837-55-4, you can also check out more blogs about1837-55-4

Reference£º
Pyridazine – Wikipedia,
Pyridazine | C4H4N1162 – PubChem

 

141-30-0, Chemistry is the science of change. But why do chemical reactions take place? Why do chemicals react with each other? The answer is in thermodynamics and kinetics.In a document type is Article, the author is Giomi, Donatella and a compound is mentioned, 141-30-0, 3,6-Dichloropyridazine, introducing its new discovery.

1-(2-Pyridyl)-2-propen-1-ol: a multipurpose reagent in organic synthesis

A peculiar thermal behaviour of hydroxyallylpyridyl derivatives, likely associated to the weak acidity of the ‘picoline-type’ hydrogen atom and responsible for the formation of allyl inversion products, has been reported. The ‘mobility’ of the same hydrogen atom allowed the unprotected title compound to behave regioselectively as C-1, C-2 or C-3 carbon nucleophile depending on the thermal or base-promoted experimental conditions and on the kind of electrophile; moreover, the corresponding Hantzsch-type pyridine tautomer displayed a biomimetic ability to transfer hydrogen to aromatic and heteroaromatic nitro derivatives.

Interested yet? Keep reading other articles of 288-14-2!, 141-30-0

Reference£º
Pyridazine – Wikipedia,
Pyridazine | C4H4N1705 – PubChem

 

64068-00-4, Catalysts function by providing an alternate reaction mechanism that has a lower activation energy than would be found in the absence of the catalyst. In a patent, 64068-00-4, molecular formula is C5H6ClN3, introducing its new discovery.

2-ALKYL-6-CYCLOAMINO-3-(PYRIDIN-4-YL)IMIDAZO[1,2-B]-PYRIDAZINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC APPLICATION THEREOF

The invention relates to 2-alkyl-6-cycloamino-3-(pyridin-4-yl)imidazo[1,2-b]pyridazine derivatives of the general formula (I) where: R2 is a C1-6-alkyl, C3-7-cycloalkyl, C3-7-cycloalkyl-C1-4-alkyl, C1-4-alkyloxy-C-M-alkyl, C3-7-cycloalkyloxy-C1-4-alkyl>C3-7-cycloalkyl-C1-4-alkyloxy-C1-4-alkyl, hydroxy-C1-6-alkyl, C1-4-fluoroalkyl group; R3 is a hydrogen atom or a substituent selected from halogen atoms and the C1-3 alkyl, ?NR4R5, hydroxyl or C1-4 alkyloxy groups; A is a C1-7-alkylene group optionally substituted by one or two Ra groups; B is a C1-7-alkylene group optionally substituted by one or two Rb groups; L is either a nitrogen atom optionally substituted by an Rc or Rd group or a carbon atom substituted by an Re1 group and an Rd group or by two Re2 groups; Rd is a group selected from a hydrogen atom or a C1-6-alkyl, C3-7-cycloalkyl, C3-7-cycloalkyl-C1-6-alkyl, C1-6-alkylthio-C1-6-alkyl, C1-6-alkyloxy-C1-6-alkyl, C1-6-fluoroalkyl, hydroxy-C1-6-alkyl group; Rf is a C1-6-alkyl, C3-7-cycloalkyl, C3-7-cycloalkyl-C1-6-alkyl, C1-6-alkyloxy-C1-6-alkyl, C3-7-cycloalkyloxy-C1-4-alkyl, C3-7-cycloalkyl-C1-4-alkyloxy-C1-4-alkyl, hydroxy-C1-6-allyl, C1-6-fluoroalkyl or benzyl group. The invention also relates to a method for preparing same and to the therapeutic application thereof.

Note that a catalyst decreases the activation energy for both the forward and the reverse reactions and hence accelerates both the forward and the reverse reactions.64068-00-4, you can also check out more blogs about64068-00-4

Reference£º
Pyridazine – Wikipedia,
Pyridazine | C4H4N1042 – PubChem

 

935777-24-5, In homogeneous catalysis, the catalyst is in the same phase as the reactant. The number of collisions between reactants and catalyst is at a maximum.In a patent, 935777-24-5, name is 6-(Trifluoromethyl)pyridazin-3-amine, introducing its new discovery.

GCN2 INHIBITORS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same.

Note that a catalyst decreases the activation energy for both the forward and the reverse reactions and hence accelerates both the forward and the reverse reactions.935777-24-5, you can also check out more blogs about935777-24-5

Reference£º
Pyridazine – Wikipedia,
Pyridazine | C4H4N2202 – PubChem